Fredholm Bertil B, Chern Yijuang, Franco Rafael, Sitkovsky Michail
Department of Physiology and Pharmacology, Karolinska Institutet, S-171 77 Stockholm, Sweden.
Prog Neurobiol. 2007 Dec;83(5):263-76. doi: 10.1016/j.pneurobio.2007.07.005. Epub 2007 Aug 1.
Many of our current hopes of finding better ways to treat Parkinson's disease or to stop its progression rely on studies of adenosine A2A receptors in the brain. Yet any drug targeting central receptors will also potentially affect receptors in other sites. Furthermore, several fundamental aspects of adenosine receptor biology must be taken into account. For these reasons the "Targeting adenosine A2A receptors in Parkinson's disease and other CNS disorders" meeting in Boston included selected aspects of the general biology of adenosine A2A receptor signaling. Some of the presentations from this part of the meeting are summarized in this first chapter. As will be apparent to the reader, these different parts do not form an integrated whole, but they do indicate areas the organizers felt might illuminate remaining questions regarding the roles of adenosine A2A receptors. The contributors to this part of the meeting have summarized some of the key questions below.
我们目前寄希望于找到更好的方法来治疗帕金森病或阻止其进展，这在很大程度上依赖于对大脑中腺苷A2A受体的研究。然而，任何针对中枢受体的药物也都有可能影响其他部位的受体。此外，还必须考虑腺苷受体生物学的几个基本方面。出于这些原因，在波士顿召开的“帕金森病和其他中枢神经系统疾病中靶向腺苷A2A受体”会议涵盖了腺苷A2A受体信号传导一般生物学的特定方面。本章总结了会议这一部分的一些发言内容。读者将会明白，这些不同部分并未形成一个完整的整体，但它们确实指出了组织者认为可能有助于阐明有关腺苷A2A受体作用的剩余问题的领域。会议这一部分的撰稿人总结了以下一些关键问题。
